Search

Search Constraints

You searched for: Author/Creator Seyedkazemi, Star

Search Results

1. 1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis. (December 2014)

2. A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Issue 5 (29th January 2018)

3. Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design: 2942. (October 2019)

4. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Issue 3 (21st July 2020)

5. Cerebrospinal fluid exposure of cenicriviroc in HIV‐positive individuals with cognitive impairment. Issue 5 (4th March 2019)

6. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism. (1st September 2018)

7. Virologic Response Rates to Fixed‐Dose Combination Ledipasvir/Sofosbuvir for 8 or 12 Weeks With Baseline Viral Load: 2061. (October 2015)